Physician profile
Megan Moser Eisel
NPI 1356445886
$2,445.92
in general payments reported to CMS, 2019-2025
22 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.26 · 2022: $213 · 2023: $187 · 2024: $940 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.37 |
| Education | $322.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $551.27 | 2022-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $307.64 | 2022-2025 | |
| Janssen Biotech, INC. | $179.02 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $165.28 | 2024-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $165.21 | 2023-2025 | Zoryve |
| Incyte Corporation | $161.18 | 2024-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $149.94 | 2025 | |
| Ucb, INC. | $115.28 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $104.98 | 2021-2025 | |
| Pfizer INC. | $99.38 | 2023-2025 | |
| Dermavant Sciences, INC. | $84.45 | 2023 | Vtama |
| Abbvie INC. | $67.32 | 2022-2025 | |
| Leo Pharma INC. | $52.45 | 2025 | Anzupgo |
| Organon LLC | $49.20 | 2025 | Vtama, Hadlima |
| Galderma Laboratories, L.P. | $33.56 | 2024-2025 | Nemluvio, Aklief |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.71 | 2024 | Sotyktu |
| Lilly USA, LLC | $23.21 | 2024 | Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.21 | 2025 | Spevigo |
| Medline Industries Lp | $21.65 | 2024 | |
| Amgen INC. | $16.57 | 2025 | Otezla |
| Verrica Pharmaceuticals INC. | $15.24 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Eisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.